Compare ENGN & CRMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENGN | CRMT |
|---|---|---|
| Founded | 1999 | 1981 |
| Country | Canada | United States |
| Employees | 82 | N/A |
| Industry | | Other Specialty Stores |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.9M | 103.5M |
| IPO Year | N/A | 2026 |
| Metric | ENGN | CRMT |
|---|---|---|
| Price | $1.64 | $7.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $21.08 | ★ $29.50 |
| AVG Volume (30 Days) | ★ 3.6M | 148.0K |
| Earning Date | 06-11-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 147.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,390,932,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.40 | $6.50 |
| 52 Week High | $12.25 | $62.55 |
| Indicator | ENGN | CRMT |
|---|---|---|
| Relative Strength Index (RSI) | 29.13 | 31.09 |
| Support Level | $1.40 | N/A |
| Resistance Level | $1.87 | $13.68 |
| Average True Range (ATR) | 0.11 | 1.31 |
| MACD | 0.20 | -0.45 |
| Stochastic Oscillator | 37.84 | 15.53 |
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.